RA Capital

Another RA-backed biotech hits Nasdaq as public market stirs again after a bruising first quarter
Endpoints
Fri, 03/25/22 - 10:29 am
AN2 Therapeutics
lung disease
funding
RA Capital
venture capital
IPOs
A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board
Endpoints
Thu, 02/10/22 - 10:27 am
GSK
Shingrix
FDA
RA Capital
Curevo Vaccine